139 related articles for article (PubMed ID: 9310126)
1. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers--a comparative study.
Höglund M; Smedmyr B; Bengtsson M; Tötterman TH; Cour-Chabernaud V; Yver A; Simonsson B
Eur J Haematol; 1997 Sep; 59(3):177-83. PubMed ID: 9310126
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
[TBL] [Abstract][Full Text] [Related]
4. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)--what is the difference?
Höglund M
Med Oncol; 1998 Dec; 15(4):229-33. PubMed ID: 9951685
[TBL] [Abstract][Full Text] [Related]
5. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
6. Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients.
Lefrère F; Bernard M; Audat F; Cavazzana-Calvo M; Belanger C; Hermine O; Arnulf B; Buzyn A; Varet B
Leuk Lymphoma; 1999 Nov; 35(5-6):501-5. PubMed ID: 10609787
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study.
Kröger N; Sonnenberg S; Cortes-Dericks L; Freiberger P; Mollnau H; Zander AR
Transfusion; 2004 Jan; 44(1):104-10. PubMed ID: 14692975
[TBL] [Abstract][Full Text] [Related]
8. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers.
Grigg AP; Roberts AW; Raunow H; Houghton S; Layton JE; Boyd AW; McGrath KM; Maher D
Blood; 1995 Dec; 86(12):4437-45. PubMed ID: 8541532
[TBL] [Abstract][Full Text] [Related]
9. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421
[TBL] [Abstract][Full Text] [Related]
10. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers.
Watts MJ; Addison I; Long SG; Hartley S; Warrington S; Boyce M; Linch DC
Br J Haematol; 1997 Aug; 98(2):474-9. PubMed ID: 9266953
[TBL] [Abstract][Full Text] [Related]
11. Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim.
Martino M; Console G; Irrera G; Callea I; Condemi A; Dattola A; Messina G; Pontari A; Pucci G; Furlò G; Bresolin G; Iacopino P; Morabito F
J Clin Apher; 2005 Oct; 20(3):129-36. PubMed ID: 15892086
[TBL] [Abstract][Full Text] [Related]
12. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
Narabayashi M; Takeyama K; Fukutomi T; Tokuda Y; Tajima T; Okumura A; Chou T; Sano M; Makino H; Igarashi T; Sasaki Y; Imoto S; Ogura M; Morishima Y; Murai H; Okamoto S; Ikeda T; Kasai M; Yokozawa T; Tobinai K
Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF.
Höglund M; Smedmyr B; Simonsson B; Tötterman T; Bengtsson M
Bone Marrow Transplant; 1996 Jul; 18(1):19-27. PubMed ID: 8831991
[TBL] [Abstract][Full Text] [Related]
14. A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Takeyama K; Ogura M; Morishima Y; Kasai M; Kiyama Y; Ohnishi K; Mitsuya H; Kawano F; Masaki Y; Sasaki T; Chou T; Yokozawa T; Tobinai K;
Jpn J Clin Oncol; 2003 Feb; 33(2):78-85. PubMed ID: 12629058
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers.
Huhn RD; Yurkow EJ; Tushinski R; Clarke L; Sturgill MG; Hoffman R; Sheay W; Cody R; Philipp C; Resta D; George M
Exp Hematol; 1996 Jun; 24(7):839-47. PubMed ID: 8647235
[TBL] [Abstract][Full Text] [Related]
16. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience.
Anderlini P; Donato M; Chan KW; Huh YO; Gee AP; Lauppe MJ; Champlin RE; Körbling M
Transfusion; 1999 Jun; 39(6):555-60. PubMed ID: 10378833
[TBL] [Abstract][Full Text] [Related]
19. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs.
Ria R; Gasparre T; Mangialardi G; Bruno A; Iodice G; Vacca A; Dammacco F
Bone Marrow Transplant; 2010 Feb; 45(2):277-81. PubMed ID: 19584820
[TBL] [Abstract][Full Text] [Related]
20. [Effect of lenograstim (glycosylated recombinant human granulocyte-colony stimulating factor) on peripheral blood stem cell mobilization in healthy volunteers].
Ohnishi A; Uchino M; Asano S
Rinsho Ketsueki; 2000 Mar; 41(3):198-205. PubMed ID: 10774248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
